NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

AVTX

Avalo Therapeutics Inc

Apr 17 • 04:00PM ET

4.41

Dollar change -0.22
Percentage change -4.75	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN AMGN BIIB GILD INCY ILMN ALNY NBIX ONC

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-161.42	Insider Own	20.47%	Shs Outstand	10.47M	Perf Week	-10.73%
Market Cap	47.06M	Forward P/E	-	EPS next Y	-4.00	Insider Trans	0.05%	Shs Float	8.49M	Perf Month	-44.81%
Income	-146.81M	PEG	-	EPS next Q	-1.18	Inst Own	56.98%	Short Float	1.36%	Perf Quarter	-34.47%
Sales	0.44M	P/S	106.95	EPS this Y	78.42%	Inst Trans	8.50%	Short Ratio	1.58	Perf Half Y	-54.49%
Book/sh	12.70	P/B	0.35	EPS next Y	11.27%	ROA	-40.91%	Short Interest	0.12M	Perf Year	-72.33%
Cash/sh	12.61	P/C	0.35	EPS next 5Y	46.00%	ROE	-50.06%	52W Range	4.44 - 17.49	Perf YTD	-40.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	56.49%	ROI	-108.44%	52W High	-74.79%	Beta	1.02
Dividend TTM	-	Quick Ratio	19.96	Sales past 5Y	9.56%	Gross Margin	167.12%	52W Low	-0.68%	ATR (14)	0.87
Dividend Ex-Date	-	Current Ratio	19.96	EPS Y/Y TTM	63.49%	Oper. Margin	-9268.25%	RSI (14)	29.58	Volatility	15.69% 14.59%
Employees	23	Debt/Eq	0.02	Sales Y/Y TTM	-77.09%	Profit Margin	-33290.93%	Recom	1.29	Target Price	33.33
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	66.88%	Payout	-	Rel Volume	1.01	Prev Close	4.63
Sales Surprise	-	EPS Surprise	-274.33%	Sales Q/Q	-66.37%	Earnings	Mar 20 BMO	Avg Volume	73.26K	Price	4.41
SMA20	-31.74%	SMA50	-37.82%	SMA200	-52.53%	Trades		Volume	73,888	Change	-4.75%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-25	Initiated	Stifel	Buy	$36
Mar-25-25	Initiated	Jefferies	Buy	$23
Feb-28-25	Initiated	Piper Sandler	Overweight	$48
Feb-21-25	Initiated	Wedbush	Outperform	$18
Dec-19-24	Initiated	BTIG Research	Buy	$40
Oct-24-24	Initiated	H.C. Wainwright	Neutral
Apr-16-24	Upgrade	Oppenheimer	Perform → Outperform	$35
Sep-24-21	Initiated	RBC Capital Mkts	Outperform	$6

Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-20-25 07:00AM	Avalo Reports 2024 Financial Results and Recent Business Updates (GlobeNewswire)
Feb-24-25 07:00AM	Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-04-25 08:00AM	Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-02-25 07:00AM	Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer (GlobeNewswire) +13.46%
06:50AM	Loading…
Dec-20-24 06:50AM	Avalo Therapeutics initiated with a Buy at BTIG (TipRanks)
Nov-12-24 07:00AM	Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants (GlobeNewswire)
Nov-11-24 07:00AM	Avalo Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 07:00AM	Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates (GlobeNewswire)
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-08-24 07:00AM	Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa (GlobeNewswire)
Sep-04-24 07:00AM	Avalo Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-12-24 07:00AM	Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -7.30%
Jul-16-24 07:00AM	Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer (GlobeNewswire)
Jul-09-24 07:00AM	Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa (GlobeNewswire)
04:01PM	Loading…
Jun-24-24 04:01PM	Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer (GlobeNewswire)
Jun-17-24 07:30AM	Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit (GlobeNewswire)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
May-24-24 01:52PM	AVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +17.49%
May-22-24 09:40AM	Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-13-24 03:52PM	AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:30AM	Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-02-24 11:30AM	Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why (Zacks) -15.31%
07:00AM	Avalo Therapeutics Appoints Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-29-24 04:01PM	Avalo Reports 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-28-24 08:04AM	Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today? (InvestorPlace) +357.89%
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
10:00AM	Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-26-24 11:28AM	Avalo (AVTX) to Report Q4 Earnings: What's in the Cards? (Zacks)
Dec-27-23 07:00AM	Avalo Therapeutics Announces 1-for-240 Reverse Stock Split (GlobeNewswire)
07:00AM	Loading…
Dec-07-23 07:00AM	Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split (GlobeNewswire) -5.61%
Nov-09-23 07:00AM	Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -10.09%
Oct-31-23 07:00AM	Avalo Completes Divestiture of AVTX-800 Series (GlobeNewswire) +18.00%
Sep-27-23 08:00AM	BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics (News Direct) +12.19%
Sep-26-23 07:00AM	Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation (GlobeNewswire) -7.36%
Sep-12-23 07:00AM	Avalo Enters into Agreement to Divest AVTX-800 Series (GlobeNewswire) +45.47%
Sep-06-23 07:00AM	Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 07:00AM	Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-06-23 04:01PM	Avalo to Participate in SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-26-23 07:00AM	Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma (GlobeNewswire) -88.69%
Jun-01-23 07:00AM	Avalo to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-22-23 07:00AM	Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board (GlobeNewswire) -11.76%
May-15-23 07:00AM	Avalo to Present at ATS 2023 Respiratory Innovation Summit (GlobeNewswire) +11.79%
May-10-23 07:00AM	Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-04-23 04:01PM	Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -5.37% -7.80%
Mar-29-23 07:30AM	Avalo Reports 2022 Financial Results and Provides Business Updates (GlobeNewswire) -7.47%
Mar-07-23 07:00AM	Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-02-23 09:54PM	Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants (GlobeNewswire)
04:01PM	Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
Jan-17-23 07:00AM	Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma (GlobeNewswire)
Nov-07-22 07:30AM	Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million (GlobeNewswire)
Sep-06-22 07:00AM	Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage (GlobeNewswire) +22.29%
Sep-01-22 07:00AM	Avalo to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-11-22 04:01PM	Avalo Therapeutics Announces Board Changes (GlobeNewswire) +6.06%
Aug-09-22 10:39AM	These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer (TipRanks) +32.14%
Aug-04-22 07:30AM	Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +10.96%
Aug-02-22 07:30AM	Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) (GlobeNewswire)
Aug-01-22 07:00AM	Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics (GlobeNewswire)
Jul-06-22 04:05PM	Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split (GlobeNewswire) -20.97%
Jun-20-22 12:10PM	Investors in Avalo Therapeutics (NASDAQ:AVTX) have unfortunately lost 90% over the last three years (Simply Wall St.)
Jun-02-22 07:30AM	Avalo to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-18-22 07:30AM	Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA) (GlobeNewswire) +6.82%
May-17-22 07:30AM	Avalo to Present at the H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) +15.08%
May-05-22 07:30AM	Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -16.27%
Mar-08-22 07:00AM	Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference (GlobeNewswire)
Mar-02-22 07:30AM	Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-17-22 07:30AM	Avalo Therapeutics Announces Leadership Transition (GlobeNewswire) -8.46%
Feb-07-22 04:01PM	Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference (GlobeNewswire)
Jan-10-22 07:59PM	Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer (GlobeNewswire) -6.20%
Jan-06-22 07:30AM	Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event (GlobeNewswire) -31.25%
Dec-16-21 07:30AM	Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022 (GlobeNewswire)
Dec-06-21 07:30AM	Avalo Appoints Two New Independent Directors to Its Board (GlobeNewswire)
Dec-05-21 06:43AM	What Type Of Shareholders Make Up Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) Share Registry? (Simply Wall St.)
Nov-11-21 07:00AM	Avalo to Present at Two Upcoming Conferences (GlobeNewswire)
Nov-09-21 04:01PM	Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-13-21 07:00AM	Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit (GlobeNewswire)
Oct-06-21 04:15PM	Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update (PR Newswire)
Sep-20-21 07:00AM	Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire) -5.91%
Sep-17-21 09:11AM	Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares (GlobeNewswire) +9.48%
Sep-14-21 10:23PM	Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock (GlobeNewswire) -9.77%
04:01PM	Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Sep-06-21 06:43AM	Avalo Therapeutics' (NASDAQ:AVTX) investors will be pleased with their favorable 35% return over the last year (Simply Wall St.)

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Almenoff June Sherie	Director	Nov 13 '24	Buy	13.00	500	6,500	1,000	Nov 14 05:21 PM
Almenoff June Sherie	Director	Nov 12 '24	Buy	12.50	500	6,250	500	Nov 14 05:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVTX

Avalo Therapeutics Inc

Upgrade your FINVIZ experience